...
首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Discriminative stimulus properties of the stereoisomers of the phosphodiesterase inhibitor rolipram.
【24h】

Discriminative stimulus properties of the stereoisomers of the phosphodiesterase inhibitor rolipram.

机译:磷酸二酯酶抑制剂咯利普兰的立体异构体的鉴别刺激特性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The discriminative stimulus properties of the specific type IV phosphodiesterase inhibitor, rolipram, and its two stereoisomers were assessed using standard two-lever drug discrimination procedures in which responding on the appropriate lever was reinforced on a FR10 schedule. In three separate drug cues based on training rats to discriminate the racemate (0.2 mg/kg, IP), the (-)-isomer (0.1 mg/kg), or the (+)-isomer (2 mg/kg) from vehicle, all forms substituted for one another, differing only in potency. In keeping with published reports, the (-)-isomer was the more potent form, the (+)-isomer being approximately 10 times less potent. Several phosphodiesterase (PDE) inhibitors were found to substitute for the racemate cue, their potencies in the behavioural measure correlating with their potency in displacing [3H]rolipram from its forebrain binding sites in vivo (r = 0.95), suggesting that the discriminative stimulus depends on an action of the drug upon this site. Because rolipram has been reported to possess antidepressant activity, the ability of the tricyclic antidepressant imipramine to substitute for rolipram was investigated; doses of 10 and 20 mg/kg did not substitute. Amphetamine (0.156-1.25 mg/kg) also was inactive. Lisuride gave rise to drug-appropriate responding in 50% of rats only at a dose of 0.078 mg/kg, which severely disrupted responding. It is concluded that the rolipram discriminative stimulus is dependent on the selective PDE inhibitory activity of the drug, and that it does not constitute a cue based on the antidepressant property of rolipram.
机译:使用标准的两杆药物区分程序评估特定IV型磷酸二酯酶抑制剂,咯利普兰及其两种立体异构体的歧视性刺激特性,其中在FR10计划中加强对适当杠杆的响应。在基于训练大鼠的三种不同药物提示中,从媒剂中区分外消旋物(0.2 mg / kg,IP),(-)-异构体(0.1 mg / kg)或(+)-异构体(2 mg / kg) ,所有形式都相互替代,只是效力不同。与公开的报道一致,(-)-异构体是更有效的形式,(+)-异构体的效力大约低10倍。发现有几种磷酸二酯酶(PDE)抑制剂可替代外消旋体提示,其行为测量方面的效力与其在体内从其前脑结合位点取代[3H]咯利普兰的效力相关(r = 0.95),这表明歧视性刺激取决于药物对该站点的作用。因为据报道咯利普兰具有抗抑郁活性,所以研究了三环类抗抑郁药丙咪嗪替代咯利普兰的能力。 10和20 mg / kg的剂量不能替代。苯丙胺(0.156-1.25 mg / kg)也没有活性。 Lisuride仅在0.078 mg / kg的剂量下才在50%的大鼠中引起适当的药物反应,这严重破坏了反应。结论是,咯利普兰的鉴别刺激取决于药物的选择性PDE抑制活性,并且基于咯利普兰的抗抑郁特性,它不构成提示。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号